Showing results (881-890 of 6,317) with videos related to

Sort By:
Pageof 632
Diabetes, Obesity & Metabolism|November 2, 2022
Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitusSung-Chen Liu, Shih-Ming Chuang, Chao-Hung Wang, et al.
Diabetes, Obesity & Metabolism|October 18, 2022
Semaglutide for the treatment of overweight and obesity: A reviewNatasha Chidekel Bergmann, Melanie J Davies, Ildiko Lingvay, et al.
Diabetes, Obesity & Metabolism|September 22, 2022
Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: A cross-sectional studyPatrick Bidulka, Rohini Mathur, David G Lugo-Palacios, et al.
Diabetes, Obesity & Metabolism|September 2, 2022
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium-glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a global federated electronic medical record databaseAmeenathul Mazaya Fawzy, José Miguel Rivera-Caravaca, Paula Underhill, et al.
Diabetes, Obesity & Metabolism|September 2, 2022
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trialRory J McCrimmon, Philip Home, Alice Cheng, et al.
Diabetes, Obesity & Metabolism|September 4, 2022
Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trialsAlhassane Diallo, Miguel Carlos-Bolumbu, Pr Eric Renard, et al.
Diabetes, Obesity & Metabolism|September 15, 2022
Mendelian randomization identifies age at menarche as an independent causal effect factor for gestational diabetes mellitusLikui Lu, Bangbei Wan, Miao Sun
Diabetes, Obesity & Metabolism|September 15, 2022
Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetesAthena Philis-Tsimikas, Harpreet S Bajaj, Kamilla Begtrup, et al.
Diabetes, Obesity & Metabolism|September 12, 2022
Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trialRosalie A Scholtes, Charlotte M Mosterd, Anne C Hesp, et al.
Diabetes, Obesity & Metabolism|October 7, 2022
Age-specific associations between the number of co-morbidities, all-cause mortality and public direct medical costs in patients with type 2 diabetes: A retrospective cohort studySabrina Nan Hong, Ivy Lynn Mak, Weng Yee Chin, et al.
Pageof 632